Maze Therapeutics - About the company
Maze Therapeutics is a public company based in Redwood City (United States), founded in 2018 by . It operates as a Developer of genetic bio-markers in neurological, metabolic, and renal diseases. Maze Therapeutics has raised $496M in funding from investors like Arch Venture Partners, Third Rock Ventures and City Hill Ventures. The company has 86 active competitors, including 29 funded and 17 that have exited. Its top competitors include companies like Metabolon, Alector and Seer.
Company Details
Maze Therapeutics is involved in developing genetic biomarkers. The company is developing technologies in an integrated manner to identify genetic modifiers. It mainly focuses on genetic modifiers in neurological, metabolic and renal diseases, as well as oncology.
- Website
- Social
- Email ID
- @mazetx.com
Key Metrics
Founded Year
2018
Location
Redwood City, United States
Stage
Public
Total Funding
in 4 rounds
Latest Funding Round
Investors
Ranked
2nd among 86 active competitors
Employee Count
as on Dec 31, 2021
Similar Companies
Exit Details
Public
Legal entities associated with Maze Therapeutics
Maze Therapeutics is associated with 2 legal entities given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
Dec 31, 1999 | - | 315 | 280 | |
Aug 28, 2017 | - | 977 | 789 |
Get your free copy of Maze Therapeutics's company profile
Maze Therapeutics's funding and investors
Maze Therapeutics has raised a total funding of $496M over 4 rounds. Its first funding round was on Mar 01, 2019. Its latest funding round was a Series D round on Dec 04, 2024 for $115M. 15 investors participated in its latest round, which includes Foresite Capital, Arch Venture Partners, Google Ventures and Janus Henderson Investors.
Maze Therapeutics has 21 institutional investors including Arch Venture Partners, Third Rock Ventures and City Hill Ventures.
Here is the list of recent funding rounds of Maze Therapeutics:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Dec 04, 2024 | $115M | Series D | 1386556 | 4025843 | |
Jan 10, 2022 | $190M | Series C | 6466649 | 7188578 | |
Oct 23, 2019 | Undisclosed | Series C | 4715970 | 2290371 |
Access funding benchmarks and valuations. Sign up today!View details of Maze Therapeutics's funding rounds and investors
Maze Therapeutics's founders and board of directors
The founders of Maze Therapeutics is . is the CEO of Maze Therapeutics.
View details of Maze Therapeutics's Founder profiles and Board Members
Maze Therapeutics's employee count trend
Maze Therapeutics has 111 employees as of Dec 21. The total employee count is 44.2% more than what it was in Dec 20. Here is Maze Therapeutics's employee count trend over the years:
Uncover Maze Therapeutics's growth story! Sign up today!Maze Therapeutics's Competitors and alternates
Top competitors of Maze Therapeutics include Metabolon, Alector and Seer. Here is the list of Top 10 competitors of Maze Therapeutics, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st | Metabolon 2000, Morrisville (United States), Series H | Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine | $181M | EW Healthcare Partners, Perceptive AdvisorsÌý&²¹³¾±è;Ìý | 72/100 |
2nd | 2018, Redwood City (United States), Public | Developer of genetic bio-markers in neurological, metabolic, and renal diseases | $496M | Foresite Capital, Arch Venture PartnersÌý&²¹³¾±è;Ìý | 64/100 |
3rd |  Alector 2013, San Francisco (United States), Public | Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders | $215M | New Leaf Venture Partners, Foresite CapitalÌý&²¹³¾±è;Ìý | 70/100 |
4th | Seer 2017, San Francisco (United States), Public | Developer of proteomics platform for early detection of cancer and neurological diseases | $128M | T. Rowe Price, HBM Healthcare InvestmentsÌý&²¹³¾±è;Ìý | 67/100 |
5th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | Third Rock Ventures, Casdin CapitalÌý&²¹³¾±è;Ìý | 66/100 |
6th | NeoPhore 2017, Cambridge (United Kingdom), Series B | Developer of small molecule therapies to treat cancer | $44.6M | Astellas Venture Management, ParkwalkÌý&²¹³¾±è;Ìý | 63/100 |
7th | Scailyte 2017, Lucerne (Switzerland), Series A | Artificial intelligence (AI) based single-cell data analysis for novel biomarker discovery | $20.3M | Zurcher Kantonalbank, MassChallengeÌý&²¹³¾±è;Ìý | 61/100 |
8th | Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public | Developer of small molecule drugs for diffrent health diseases | - | New Enterprise Associates, Bay City CapitalÌý&²¹³¾±è;Ìý | 60/100 |
9th | Denovo Biopharma 2013, San Diego (United States), Series D | Developer of genomic biomarker discovery platform | $172M | CICC, Goldstone Investment Ìý&²¹³¾±è;Ìý | 59/100 |
10th | Provider of a technology platform for the discovery of antibody-based drugs | $180M | Sequoia Capital, IDG CapitalÌý&²¹³¾±è;Ìý | 58/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Maze Therapeutics's competitors? Click to see the top ones
Maze Therapeutics's Investments and acquisitions
Maze Therapeutics has made no investments or acquisitions yet.
Reports related to Maze Therapeutics
Here is the latest report on Maze Therapeutics's sector:
View
News related to Maze Therapeutics
Media has covered Maze Therapeutics for a total of 17 events in the last 1 year, 9 of them have been about company updates.
•
•
•
•
•
Pharmaceutical Technology•Dec 04, 2024•Maze Therapeutics, Deep Track Capital, Frazier Life Sciences, Logos and 7 others
•
Business Wire•Dec 03, 2024•Maze Therapeutics, Frazier Life Sciences, Deep Track Capital, Logos and 10 others
•
Fierce Biotech•Dec 03, 2024•Maze Therapeutics, Frazier Life Sciences, Deep Track Capital, Janus Henderson Investors and 4 others
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Frequently asked questions about Maze Therapeutics
When was Maze Therapeutics founded?
Maze Therapeutics was founded in 2018.Where is Maze Therapeutics located?
Maze Therapeutics is located in Redwood City, United States.When was the latest funding round of Maze Therapeutics?
Maze Therapeutics's latest funding round was on Dec 04, 2024.What is the annual revenue of Maze Therapeutics?
Annual revenue of Maze Therapeutics is undefined as on undefined.Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
Explore our recently published companies
- Srbagroup - Unfunded company
- Kevis - Hyderabad based, 2016 founded, Unfunded company
- Location Media Xchange - Singapore based, 2020 founded, Unfunded company
- Flipshop Pro - 2024 founded, Unfunded company
- Zenevista - Lagos based, 2024 founded, Unfunded company
- Direct Jobs UK - Chicago based, 2024 founded, Unfunded company
